An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Biologic License Application (BLA): 022575
Company: SHIRE HUMAN GENETIC

This Former NDA Was Deemed To Be a BLA on March 23, 2020.

Products on BLA 022575

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
VPRIV	VELAGLUCERASE ALFA	400 UNITS/VIAL	INJECTABLE;INTRAVENOUS	Prescription	None	No	No
VPRIV	VELAGLUCERASE ALFA	200 UNITS/VIAL	POWDER;INTRAVENOUS	Discontinued	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for BLA 022575

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
02/26/2010	ORIG-1	Approval		N/A; Orphan	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022575lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022575s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022575s000TOC.html

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
07/10/2024	SUPPL-30	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022575s030lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022575Orig1s030ltr.pdf
12/10/2020	SUPPL-26	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022575s026lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/022575Orig1s026ltr.pdf
11/06/2019	SUPPL-23	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022575s023lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/022575Orig1s023ltr.pdf
07/30/2019	SUPPL-22	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022575s022lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/022575Orig1s022ltr.pdf
01/11/2016	SUPPL-18	Supplement		Label is not available on this site.
05/05/2015	SUPPL-17	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022575s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022575Orig1s017ltr.pdf
02/03/2015	SUPPL-16	Supplement		Label is not available on this site.
12/02/2014	SUPPL-15	Supplement		Label is not available on this site.
06/18/2014	SUPPL-14	Supplement		Label is not available on this site.
10/02/2013	SUPPL-13	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022575Orig1s013ltr.pdf
11/21/2013	SUPPL-12	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022575Orig1s012ltr.pdf
06/03/2013	SUPPL-11	Supplement		Label is not available on this site.
07/11/2014	SUPPL-10	Supplement		Label is not available on this site.
03/26/2013	SUPPL-9	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s007s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022575Orig1s007,s009ltr.pdf
02/11/2014	SUPPL-8	Supplement		Label is not available on this site.
03/26/2013	SUPPL-7	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s007s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022575Orig1s007,s009ltr.pdf

Labels for BLA 022575

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
07/10/2024	SUPPL-30	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022575s030lbl.pdf
12/10/2020	SUPPL-26	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022575s026lbl.pdf
11/06/2019	SUPPL-23	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022575s023lbl.pdf
07/30/2019	SUPPL-22	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022575s022lbl.pdf
05/05/2015	SUPPL-17	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022575s017lbl.pdf
11/21/2013	SUPPL-12	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s012lbl.pdf
10/02/2013	SUPPL-13	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s013lbl.pdf
03/26/2013	SUPPL-9	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s007s009lbl.pdf
03/26/2013	SUPPL-7	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s007s009lbl.pdf
02/26/2010	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022575lbl.pdf

Top